Clinical trial
A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) With or Without Ipilimumab (BMS-734016) in Patients With Advanced Renal Cell Carcinoma in Real Life Setting
NCT03455452 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) With or Without Ipilimumab (BMS-734016) in Patients With Advanced Renal Cell Carcinoma in Real Life Setting
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Observational
- Overall status
- Completed
- Start date
- January 21, 2018
- Completion date
- December 18, 2025
- Enrollment
- 623 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
adenocarcinoma of kidney, adenocarcinoma, renal cell, cancer of the kidney, kidney cancer, renal cell cancer, renal cell carcinoma